Clinical Scorecard: Risk of Subsequent Primary Cancers in Patients Diagnosed With Neuroendocrine Tumors
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Risk of Subsequent Primary Cancers in Patients Diagnosed With Neuroendocrine Tumors
Key Mechanisms
Analytic approach: time-varying Fine-Gray competing-risk models treated death before SPC as a competing event.
Target Population
Population described in the source article.
Care Setting
Care setting described in the source article.
Key Highlights
During a median 47-month follow-up, 7.41% of the cohort developed an SPC.
SPCs occurred in 4.97% of patients with early-onset NETs and 8.06% of those with average-onset NETs.
Adjusted SPC subdistribution hazard ratios for early-onset versus average-onset NET were 0.35 at 1 year, 0.59 at 5 years, and 0.73 at 10 years.
Among patients with early-onset NET, gastric, pancreatic, and small-intestinal primary sites were associated with higher SPC risk; appendiceal NETs were associated with lower risk.
The authors state that these findings do not support modifying established population-based cancer screening recommendations.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
The authors state that future survivorship strategies may need to account for demographic and disease-specific features associated with SPC occurrence.
Risks
Patient & Prescribing Data
Registry cohort of 95,625 patients with NETs diagnosed from 2000 through 2021; 20,119 (21.04%) had early-onset disease, defined as age younger than 50 years.
The study evaluated SPC risk and did not report treatment or prescribing comparisons.
Clinical Best Practices
The adjusted relative subdistribution hazard for early-onset versus average-onset NET increased from 0.35 at 1 year to 0.73 at 10 years.
Among patients with early-onset NET, gastric, pancreatic, and small-intestinal primary sites were associated with higher SPC risk, while appendiceal NETs were associated with lower risk.
The authors state that the findings do not support modifying established population-based cancer screening recommendations; site-specific incidence was not compared with the general population.